

## CURRICULUM VITAE

Name: **Edwin Duncan Charlebois III**  
Position: Assistant Adjunct Professor, Step 5  
Department of Medicine  
School of Medicine

Address: Center for AIDS Prevention Studies  
50 Beale St., 13<sup>th</sup> Floor  
Room 13045, Box 0886  
San Francisco, CA. 94105

Voice: (415) 597-9301  
Fax: (415) 597-9213  
Email: Edwin.Charlebois@UCSF.edu

### **EDUCATION:**

1979-84	Univ. of Calif. Berkeley	B.A.	Genetics
1988-90	Univ. of Calif. Berkeley	M.P.H.	Epidemiology - Biostatistics
1994-98	Univ. of Calif. Berkeley	Ph.D.	Epidemiology
1995-97	UCSF Center for AIDS Prevention Studies	Fellowship	AIDS/HIV Research

### **PRINCIPAL POSITIONS HELD:**

1985-86	Univ. of Calif. Berkeley, Dept. of Neurobiology	Staff Research Associate I
1986-91	Univ. of Calif. San Francisco, Pediatric Oncology	Clinical Research Asst. II
1991-92	Univ. of Calif. San Francisco, Epidemiology	Statistician
1992-98	Univ. of Calif. San Francisco, Epidemiology	Associate Specialist & Senior Statistician
1995-96	UCSF Center for AIDS Research, Biostatistics	Sub-Core Director
1997-98	UCSF Center for AIDS Prevention Studies	Associate Specialist
1998-98	Univ. of Calif. San Francisco, Epidemiology	Specialist
1999-now	Univ. of Calif. San Francisco, Dept. of Medicine, Division of Infectious Diseases	Assistant Adj. Professor
2000-03	Center for Excellence in Patient Research: Soft-Tissue Infection Program	Director
2003-now	AIDS Policy Research Center Prevention Research UCSF Center for AIDS Prevention Studies	Co-Director
2004-now	National Evaluation Center AIDS Education and Training Centers Health Resources and Services Administration US Department of Health and Human Services	Co-Principal Investigator

### **ANCILLARY POSITIONS HELD CONCURRENTLY:**

1985-86	Holocaust Research Center, San Francisco, CA.	Computer Consultant
1986-87	Ralph K. Davies Med. Center, Stonewall Med. Grp.	Clinical Research Associate
1989-91	LifeSource, Inc., San Francisco, CA.	Consulting Statistician

### **HONORS AND AWARDS:**

1981	San Francisco Cable Car Award for public service in health education
1995	Center for AIDS Prevention Studies - Predoctoral Fellowship in AIDS/HIV
1996	Center for AIDS Prevention Studies - Predoctoral Fellowship in AIDS/HIV
2001	Center for Excellence in Patient Research Award - UCSF
2001	Hellman Family Award for Early Career Faculty - UCSF
2001	SFGH Medical Center Career Award Recipient

### **KEYWORDS/AREAS OF INTEREST:**

Human Immunodeficiency Virus (HIV), epidemiology, biostatistics, prevention, policy, clinical trials, medication adherence, Tuberculosis, Malaria, co-infection, operations research, stigma, antibiotic resistance, Methicillin-Resistant *Staph. aureus* (MRSA)

### **PROFESSIONAL ORGANIZATIONS:**

1988-now	Society for Epidemiologic Research
1988-now	American Public Health Association
1992-now	International Genetic Epidemiology Society
1992-now	International AIDS Society
2001-2004	American Society for Microbiology

### **SERVICE TO PROFESSIONAL PUBLICATIONS:**

2000-06	Ad hoc referee for Clinical Infectious Diseases (5 papers)
2000-06	Ad hoc referee for Journal of Infectious Diseases (3 papers)
2003-04	Ad hoc referee for Current Drug Targets (1 paper)
2003-04	Ad hoc referee for American Journal of Medicine (1 paper)
2003-04	Ad hoc referee for Emerging Infectious Diseases (2 papers)
2003-06	Ad hoc referee for Journal of AIDS (6 papers)
2004-06	Ad hoc referee for Journal of AIDS (5 papers/abstracts)
2004-05	Ad hoc referee for Infection Control and Hospital Epidemiology (2 papers)

## **INVITED PRESENTATIONS:**

### **INTERNATIONAL**

International Conference on AIDS, 1998 (abstract x4), 2004 (abstract x2)  
International Genetic Epidemiology Society, 1992  
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2000 (abstract),  
2001 (abstract x3), 2002 (abstract)  
Makerere University, Uganda, HIV and Tuberculosis Update, 2004 (presentation)

### **NATIONAL**

Epidemiology and Prevention of Infectious Diseases: Hospital-Associated Infections, 2001  
Infectious Disease Society of America, 2002 (invited presentation), 2003 (poster)  
Positive Populations Meeting, 2004 (invited presentation)  
National AIDS Drug Assistance Program (ADAP) Educational Conference, 2005 (invited lecture)

### **REGIONAL AND OTHER INVITED PRESENTATIONS**

1998 CDC Experts Meeting on Community-Onset Methicillin-Resistant *Staphylococcus aureus*  
(Invited community MRSA Expert)  
2000 Centers for Disease Control: Community-Acquired *Staphylococcus aureus* Infections  
Meeting (Invited Speaker)  
2000 California Emerging Infections Program Meeting (Invited Presentation)  
2001 UCSF Surgery Grand Rounds: (Invited Speaker)  
2003 San Francisco General Hospital HIV Grand Rounds (Invited Speaker)  
2003 California Pacific Medical Center Grand Rounds (Invited Speaker)  
2003 Case Western Reserve University TBRU Grand Rounds (Invited Speaker)  
2003 San Francisco Community Forum on Drug Resistant Staph Infections (Invited Speaker)  
2003 California State HIV Surveillance Workgroup Meeting (Invited Speaker)  
2003 Acceptability of Non-Name HIV Surveillance. California State Office of AIDS (Invited  
Speaker)  
2003 Global HIV Update - World AIDS Day Celebration–, Kaiser-Permanente (Keynote  
Speaker)  
2004 Center for AIDS Prevention Studies Community Conference (Speaker)  
2005 Center for AIDS Prevention Studies Community Conference (Speaker)

### **POSTGRADUATE AND CONTINUING EDUCATION COURSES ATTENDED:**

1994	1 day	Univ. of Calif. Berkeley	Scientific Researchers and the Media
2000	1 day	NIH Office of Human Subjects	Protection of Human Subjects
2001	3 days	Univ. of Calif. San Francisco	Hospital-Acquired Infections
2002	1 day	UCSF Comm. Human Research	Basic Certification in Protection of Human Subjects
2002	1 day	IDSA Bacteriology Symposium	Molecular Basis for Drug Resistance

**GOVERNMENT and OTHER PROFESSIONAL SERVICE:**

1990-92 San Francisco Community Consortium Data Safety Monitoring Board  
1992-98 San Francisco Community Consortium Scientific Advisory Board  
1999-04 California Emerging Infections Program  
2002-now NIH Data Safety Monitoring Board – Clinical trial of Short-Course TB treatment  
2004-05 Positive Populations Advisory Board

**UNIVERSITY SERVICE:**

**SYSTEM WIDE:**

1994-2005 University Wide AIDS Research Program ADAP Research Task Force  
2006-2007 University Wide AIDS Research Program Ryan White Care Act Reauthorization,  
Severity of Need Task Force

**CAMPUS WIDE:**

1995-1997 Chancellor's Committee on the Status of Women (Research Consultant)  
2005-2006 UCSF Junior Faculty AIDS Researchers (jFAR) Steering Committee

**DEPARTMENT: Epidemiology & Biostatistics**

1995-1999 Departmental Computer Committee

**DEPARTMENT: Medicine**

1998-2003 Infection Control Committee (SFGH)  
1998-2002 Hospital Computer Committee (CHN/SFGH)  
1999-2004 Community Health Network Data Governance Committee  
2003-2005 UCSF Prevention Sciences Group Computer Committee  
2004-2006 Center for AIDS Prevention Studies Pilot Grant Review Committee  
2004-2006 UCSF AIDS Research Institute Mentored Scientist Award Review Committee  
2005-2006 UCSF Center for AIDS Research Pilot Grant Award Review Committee  
2005-2006 Center for AIDS Prevention Studies / Pacific AIDS Education and Training Centers  
Computer Users Committee (Chair)

**PUBLIC SERVICE**

2002-2003 California Camp-To-Belong for Foster Kids (counselor, camp photographer)

## **TEACHING and MENTORING**

### **POSTGRADUATE COURSES SPONSORED BY UCSF:**

- 1992 2nd Regional Symposium on the Design and Methods of Clinical Trials,  
(Small group presentation).
- 1993 3rd Regional Symposium on the Design and Methods of Clinical Trials,  
(Lecture: Large Simple Trials)
- 1993 3rd Regional Symposium on the Design and Methods of Clinical Trials,  
(Lecture: Intent-to-Treat versus Per-Protocol Analysis)

### **PREDOCTORAL STUDENTS SUPERVISED OR MENTORED**

<b>Dates</b>	<b>Name</b>	<b>Program or School</b>	<b>Role</b>	<b>Current Position</b>
2000-2003	Nicolas Moss	UC Berkeley	Research Supervisor	UCI Med Sch
2005-2006	Samuel Singer	UC Berkeley	Research Supervisor	UCSF/UCB Joint Medical Program
2005-2006	Aliza Monroe	Stanford University	Research Supervisor	Stanford Med Sch
2005-2006	Starley Shade	UC Berkeley	Academic Career Mentor	UCB Grad Student

### **POSTDOCTORAL STUDENTS and FELLOWS SUPERVISED OR MENTORED**

<b>Dates</b>	<b>Name</b>	<b>Program or School</b>	<b>Role</b>	<b>Current Position</b>
2000-2003	Erica Pan, MD PhD	UCSF ID Fellowship	Research Mentor	UCSF Clinical Instructor
2000-2003	Christopher Hall, MD	UCSF ID Fellowship	Research Mentor	UCSF Asst. Adj. Professor
2003-2006	Padmini Srikantiah, MD	UCSF – CAPS TAPS Fellowship	TAPS Co-Mentor	UCSF ID Fellow
2003-2006	Anne Luetkemeyer, MD	UCSF – CAPS TAPS Fellowship	TAPS Co-Mentor	UCSF ID Fellow
2003-2006	Wayne Steward, PhD, MPH	UCSF – CAPS TAPS Fellowship	Academic Career Mentor	UCSF Research Specialist

### **FACULTY MENTORED**

<b>Dates</b>	<b>Name</b>	<b>Mentored Position</b>	<b>Mentoring Role</b>	<b>Current Position</b>
2004-2006	Maria Ekstrand, PhD	Assistant Professor	Research collaborator & reviewed grant applications	UCSF Asst. Prof.
2005-2006	Huyen Cao, MD	Clinical Instructor	Reviewed grant applications	Director CA. DHS VRD Laboratory
2005-2006	Tri Do, MD	Assistant Professor	Reviewed grant applications	UCSF Asst. Prof.
2005-2006	Janet Myers, PhD MPH	Assistant Professor	Informal Career Advisor	UCSF Asst. Prof.

**OTHER TEACHING:**

Scheduled Teaching:

2000-now CAPS Scientific Writing Seminar (10 students, 2 hrs, every other week)

Informal (Bench Teaching):

1994-now Research Design Graduate Nursing and Public Health Students

1994-now Data Analysis UCSF Faculty, Staff, and Students

**SUMMARY OF TEACHING HOURS:**

2004-2005 xxx Total Hours of Teaching (including preparation)

Formal class or course teaching hours:

Informal teaching hours:

Mentoring hours:

2005-2006 xxx Total Hours of Teaching (including preparation)

Formal class or course teaching hours:

Informal teaching hours:

Mentoring hours:

**TEACHING NARRATIVE**

## **RESEARCH AND CREATIVE ACTIVITY:**

### **RESEARCH AWARDS AND GRANTS**

#### **CURRENT**

R01 MH75637-01A1 (Principal Investigator) NIH/NIMH Family-Based HIV VCT for Patients at Risk for TB	04/01/06-3/30/11 \$508,692 direct/yr 1 \$2,432,875 direct/yrs1-5
U69 HA02501-01-00 (Co-Principal Investigator) HRSA AIDS Education and Training Centers (AETC): National Evaluation Center	3/1/2004-2/29/2007 \$412,303 direct/yr 1 \$1,350,000 direct/yrs1-3
UARP-RWCA/SON (Co-Principal Investigator) University Wide AIDS Research Program Modeling the Impact of Ryan White Care Act Severity of Need Indices	04/01/06-09/30/06 \$250,000 direct/yr1
U01 AI062677-01 (Co-Investigator) NIH/NIAID Clinical Studies of Interactions between HIV and Malaria	09/30/2004-5/31/2009 \$556,075 direct/yr 1 \$3,991,102 direct/yrs1-5
RO1 MH57616-01A1 (Co-Investigator) NIH/NIMH Health-Related Interventions for Persons Living with HIV	8/01/98-7/31/05 \$817,840 direct/yr 1 \$4,943,138 direct/yrs1-7
R01 AI01219-O1A2 (Co-Investigator) NIH/NIAID HIV/TB in Uganda: Punctuated Antiretroviral Therapy	05/13/03-02/28/08 \$388,726 direct/yr 1

#### **PAST**

San Francisco Department of Public Health MOU (Principal Investigator) Supplement to Randomized Controlled Trial of a Multi-infection Testing and Counseling	9/30/00-9/29/03 \$58,215
California Emerging Infections Program Grant (Principal Investigator) Centers for Disease Control ISIS Cohort Study II: Recurrent MRSA in Soft-Tissue Infections	12/30/01-12/29/02 \$24,967
Early Career Faculty Award (Principal Investigator) Hellman Family Fund Reducing Drug Resistant Community-Acquired Infections	10/18/01-10/17/02 \$49,000

Center for Excellence in Patient Research (Principal Investigator) UCSF School of Medicine ISIS Cohort Study: The Molecular Epidemiology of <i>S. aureus</i> Soft-Tissue Infections	4/1/01-4/1/02 \$60,000
California Emerging Infections Program Grant (Principal Investigator) Centers for Disease Control ISIS Cohort Study I: Community-Acquired MRSA in Soft-Tissue Infections	12/30/00-12/29/01 \$24,234
California Emerging Infections Program Grant (Principal Investigator) Centers for Disease Control SNIF: Prevalence of MRSA in the Urban Poor	12/30/99-12/29/00 \$47,000
UARP Award #AD03-SF-600 (Co-Investigator) University Wide AIDS Research Program AIDS Drug Assistance Program Financing and Research Initiative	2004 \$120,000
CA-SOA 02-25870 (Co-Investigator) State of California, Office of AIDS Evaluating the Acceptability of California's Non-Name HIV Surveillance System.	2001-2004 \$900,000
No Award # (Co-Investigator) National Association of Community Health Centers award Nationwide Evaluation of HIV testing, policies and procedures at Community Health Centers.	2004 \$51,000
R01 MH54907-08 (Co-Investigator) NIH/NIMH Protease Inhibitors in the Homeless: A Cohort	02/01/02-01/31/05 \$2,278,797
R01 MH64388-01 (Co-Investigator) NIH/NIMH A RCT of HIV Adherence Case Management and Modified DOT	04/01/02-03/31/07 \$3,010,420
R01 MH63011-01A1 (Co-Investigator) NIH/NIMH Depression Treatment to Improve ARV Therapy	10/01/01-09/30/06 \$2,278,797
California Emerging Infections Program Grant (Co-Investigator) Centers for Disease Control Community-Acquired Methicillin Resistant <i>Staphylococcus aureus</i> Infections Among Urban Youth	12/30/02-12/29/03 \$28,020
R01 MH54907-04A1 (Co-Investigator) NIH/NIMH Protease Inhibitors in the Homeless: A Cohort Study	2/1/99 – 1/31/2002 \$2,825,510

Evaluation Research on HIV Prevention Interventions (Co-Investigator) 4/1/00 – 3/31/03  
University-wide Aid Research Program \$499,325  
Prospective Outcome Evaluation of Care Coordination In San Francisco

Doris Duke Charitable Foundation (Co-Investigator) 7/1/00-6/30/05  
Doris Duke Clinical Scholars Program \$500,000  
Antiretroviral outcomes research in the HIV+ urban poor.

### **PEER REVIEWED PUBLICATIONS**

1. Veugelers PJ, Schechter MT, Tindall B, Moss AR, Page KA, Craib KJ, Cooper DA, Coutinho RA, **Charlebois E**, Winkelstein W, Jr., et al. Differences in time from HIV seroconversion to CD4+ lymphocyte end-points and AIDS in cohorts of homosexual men. *Aids*. Oct 1993;7(10):1325-1329.
2. Sanchez-Pescador L, Pereira L, **Charlebois ED**, Kohl S. Antibodies to epitopes of herpes simplex virus type 1 glycoprotein B (gB) in human sera: analysis of functional gB epitopes defined by inhibition of murine monoclonal antibodies. *J Infect Dis*. Oct 1993;168(4):844-853.
3. Jacobson MA, Yajko D, Northfelt D, **Charlebois E**, Gary D, Brosgart C, Sanders CA, Hadley WK. Randomized, placebo-controlled trial of rifampin, ethambutol, and ciprofloxacin for AIDS patients with disseminated Mycobacterium avium complex infection. *J Infect Dis*. Jul 1993;168(1):112-119.
4. Sheppard H, Winkelstein W, Lang W, **Charlebois E**. CD4+ T-lymphocytopenia without HIV infection. *N Engl J Med*. Jun 24 1993;328(25):1847-1848.
5. Osmond DH, **Charlebois E**, Sheppard HW, Page K, Winkelstein W, Moss AR, Reingold A. Comparison of risk factors for hepatitis C and hepatitis B virus infection in homosexual men. *J Infect Dis*. Jan 1993;167(1):66-71.
6. Veugelers PJ, Page KA, Tindall B, Schechter MT, Moss AR, Winkelstein WW, Jr., Cooper DA, Craib KJ, **Charlebois E**, Coutinho RA, et al. Determinants of HIV disease progression among homosexual men registered in the Tricontinental Seroconverter Study. *Am J Epidemiol*. Oct 15 1994;140(8):747-758.
7. Jenkins M, Landers D, Williams-Herman D, Wara D, Viscarello RR, Hammill HA, Kline MW, Shearer WT, **Charlebois ED**, Kohl S. Association between anti-human immunodeficiency virus type 1 (HIV-1) antibody-dependent cellular cytotoxicity antibody titers at birth and vertical transmission of HIV-1. *J Infect Dis*. Aug 1994;170(2):308-312.
8. Osmond D, **Charlebois E**, Lang W, Shiboski S, Moss A. Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983 to 1993. *Jama*. Apr 13 1994;271(14):1083-1087.

9. Stanley HD, **Charlebois E**, Harb G, Jacobson MA. Central venous catheter infections in AIDS patients receiving treatment for cytomegalovirus disease. *J Acquir Immune Defic Syndr*. Mar 1994;7(3):272-278.
10. Busch MP, Valinsky JE, Paglieroni T, Prince HE, Crutcher GJ, Gjerset GF, Operskalski EA, **Charlebois E**, Bianco C, Holland PV, et al. Screening of blood donors for idiopathic CD4+ T-lymphocytopenia. *Transfusion*. Mar 1994;34(3):192-197.
11. Wachter RM, Luce JM, Safrin S, Berrios DC, **Charlebois E**, Scitovsky AA. Cost and outcome of intensive care for patients with AIDS, *Pneumocystis carinii* pneumonia, and severe respiratory failure. *Jama*. Jan 18 1995;273(3):230-235.
12. Northfelt DW, **Charlebois ED**, Mirda MI, Child C, Kaplan LD, Abrams DI. Continuous low-dose interferon-alpha therapy for HIV-related immune thrombocytopenic purpura. *J Acquir Immune Defic Syndr Hum Retrovirol*. Jan 1 1995;8(1):45-50.
13. Osmond DH, **Charlebois E**, Moss AR. Bias in observational studies of treatment. *Ann Intern Med*. Dec 1 1996;125(11):941.
14. Kohl S, Sigaroudinia M, **Charlebois ED**, Jacobson MA. Interleukin-12 administered in vivo decreases human NK cell cytotoxicity and antibody-dependent cellular cytotoxicity to human immunodeficiency virus-infected cells. *J Infect Dis*. Nov 1996;174(5):1105-1108.
15. Brosgart CL, Mitchell T, **Charlebois E**, Coleman R, Mehalko S, Young J, Abrams DI. Off-label drug use in human immunodeficiency virus disease. *J Acquir Immune Defic Syndr Hum Retrovirol*. May 1 1996;12(1):56-62.
16. Slome LR, Mitchell TF, **Charlebois E**, Benevedes JM, Abrams DI. Physician-assisted suicide and patients with human immunodeficiency virus disease. *N Engl J Med*. Feb 6 1997;336(6):417-421.
17. Stansell JD, Osmond DH, **Charlebois E**, LaVange L, Wallace JM, Alexander BV, Glassroth J, Kvale PA, Rosen MJ, Reichman LB, Turner JR, Hopewell PC. Predictors of *Pneumocystis carinii* pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. *Am J Respir Crit Care Med*. Jan 1997;155(1):60-66.
18. Grant RW, **Charlebois ED**, Wachter RM. Risk factors for early hospital readmission in patients with AIDS and pneumonia. *J Gen Intern Med*. Sep 1999;14(9):531-536.
19. Morin SF, **Charlebois ED**. Expanding access to early HIV care: new challenges for federal health policy. *AIDS Public Policy J*. Summer 2000;15(2):65-74.
20. Bangsberg DR, Hecht FM, **Charlebois ED**, Zolopa AR, Holodniy M, Sheiner L, Bamberger JD, Chesney MA, Moss A. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. *Aids*. Mar 10 2000;14(4):357-366.
21. Elbeik T, **Charlebois E**, Nassos P, Kahn J, Hecht FM, Yajko D, Ng V, Hadley K. Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1

- RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor monitor version 1.5. *J Clin Microbiol.* Mar 2000;38(3):1113-1120.
22. Kohl S, **Charlebois ED**, Sigouroudinia M, Goldbeck C, Hartog K, Sekulovich RE, Langenberg AG, Burke RL. Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine. *J Infect Dis.* Jan 2000;181(1):335-339.
  23. Staedke SG, Kanya MR, Dorsey G, Gasasira A, Ndeezi G, **Charlebois ED**, Rosenthal PJ. Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. *Lancet.* Aug 4 2001;358(9279):368-374.
  24. Bangsberg DR, Perry S, **Charlebois ED**, Clark RA, Roberston M, Zolopa AR, Moss A. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. *Aids.* Jun 15 2001;15(9):1181-1183.
  25. Bangsberg DR, Hecht FM, Clague H, **Charlebois ED**, Ciccarone D, Chesney M, Moss A. Provider assessment of adherence to HIV antiretroviral therapy. *J Acquir Immune Defic Syndr.* Apr 15 2001;26(5):435-442.
  26. Winston LG, Bangsberg DR, Chambers HF, 3rd, Felt SC, Rosen JI, **Charlebois ED**, Wong M, Steele L, Gerberding JL, Perdreau-Remington F. Epidemiology of vancomycin-resistant *Enterococcus faecium* under a selective isolation policy at an urban county hospital. *Am J Infect Control.* Nov 2002;30(7):400-406.
  27. **Charlebois ED**, Bangsberg DR, Moss NJ, Moore MR, Moss AR, Chambers HF, Perdreau-Remington F. Population-based community prevalence of methicillin-resistant *Staphylococcus aureus* in the urban poor of San Francisco. *Clin Infect Dis.* Feb 15 2002;34(4):425-433.
  28. Johnson MO, Catz SL, Remien RH, Rotheram-Borus MJ, Morin SF, **Charlebois E**, Gore-Felton C, Goldsten RB, Wolfe H, Lightfoot M, Chesney MA. Theory-guided, empirically supported avenues for intervention on HIV medication nonadherence: findings from the Healthy Living Project. *AIDS Patient Care STDS.* Dec 2003;17(12):645-656.
  29. Pan ES, Diep BA, Carleton HA, **Charlebois ED**, Sensabaugh GF, Haller BL, Perdreau-Remington F. Increasing prevalence of methicillin-resistant *Staphylococcus aureus* infection in California jails. *Clin Infect Dis.* Nov 15 2003;37(10):1384-1388.
  30. Bangsberg DR, **Charlebois ED**, Grant RM, Holodniy M, Deeks SG, Perry S, Conroy KN, Clark R, Guzman D, Zolopa A, Moss A. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. *Aids.* Sep 5 2003;17(13):1925-1932.
  31. Hahn JA, Bangsberg DR, McFarland W, **Charlebois ED**, Clark RA, Moss AR. HIV seroconversion among the homeless and marginally housed in San Francisco: a ten-year study. *J Acquir Immune Defic Syndr.* Dec 15 2004;37(5):1616-1619.

32. Winston LG, **Charlebois ED**, Pang S, Bangsberg DR, Perdreau-Remington F, Chambers HF. Impact of a formulary switch from ticarcillin-clavulanate to piperacillin-tazobactam on colonization with vancomycin-resistant enterococci. *Am J Infect Control*. Dec 2004;32(8):462-469.
33. Carleton HA, Diep BA, **Charlebois ED**, Sensabaugh GF, Perdreau-Remington F. Community-adapted methicillin-resistant *Staphylococcus aureus* (MRSA): population dynamics of an expanding community reservoir of MRSA. *J Infect Dis*. Nov 15 2004;190(10):1730-1738.
34. Moss AR, Hahn JA, Perry S, **Charlebois ED**, Guzman D, Clark RA, Bangsberg DR. Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study. *Clin Infect Dis*. Oct 15 2004;39(8):1190-1198.
35. Myers JJ, Steward WT, **Charlebois E**, Koester KA, Maiorana A, Morin SF. Written clinic procedures enhance delivery of HIV "prevention with positives" counseling in primary health care settings. *J Acquir Immune Defic Syndr*. Oct 1 2004;37 Suppl 2:S95-S100.
36. Young DM, Harris HW, **Charlebois ED**, Chambers H, Campbell A, Perdreau-Remington F, Lee C, Mankani M, Mackersie R, Schechter WP. An epidemic of methicillin-resistant *Staphylococcus aureus* soft tissue infections among medically underserved patients. *Arch Surg*. Sep 2004;139(9):947-951; discussion 951-943.
37. Holodniy M, **Charlebois ED**, Bangsberg DR, Zolopa AR, Schulte M, Moss AR. Prevalence of antiretroviral drug resistance in the HIV-1-infected urban indigent population in San Francisco: a representative study. *Int J STD AIDS*. Aug 2004;15(8):543-551.
38. Oyugi JH, Byakika-Tusiime J, **Charlebois ED**, Kityo C, Mugerwa R, Mugenyi P, Bangsberg DR. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. *J Acquir Immune Defic Syndr*. Aug 15 2004;36(5):1100-1102.
39. Robertson MJ, Clark RA, **Charlebois ED**, Tulskey J, Long HL, Bangsberg DR, Moss AR. HIV seroprevalence among homeless and marginally housed adults in San Francisco. *Am J Public Health*. Jul 2004;94(7):1207-1217.
40. **Charlebois ED**, Perdreau-Remington F, Kreiswirth B, Bangsberg DR, Ciccarone D, Diep BA, Ng VL, Chansky K, Edlin BR, Chambers HF. Origins of community strains of methicillin-resistant *Staphylococcus aureus*. *Clin Infect Dis*. Jul 1 2004;39(1):47-54.
41. Bangsberg DR, Porco TC, Kagay C, **Charlebois ED**, Deeks SG, Guzman D, Clark R, Moss A. Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. *J Infect Dis*. Jul 1 2004;190(1):162-165.
42. Kagay CR, Porco TC, Liechty CA, **Charlebois E**, Clark R, Guzman D, Moss AR, Bangsberg DR. Modeling the impact of modified directly observed antiretroviral therapy on HIV suppression and resistance, disease progression, and death. *Clin Infect Dis*. Jun 1 2004;38 Suppl 5:S414-420.

43. Giordano TP, Guzman D, Clark R, **Charlebois ED**, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. *HIV Clin Trials*. Mar-Apr 2004;5(2):74-79.
44. Liechty CA, Alexander CS, Harrigan PR, Guzman JD, **Charlebois ED**, Moss AR, Bangsberg DR. Are untimed antiretroviral drug levels useful predictors of adherence behavior? *Aids*. Jan 2 2004;18(1):127-129.
45. Porco TC, Martin JN, Page-Shafer KA, Cheng A, **Charlebois E**, Grant RM, Osmond DH. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. *Aids*. Jan 2 2004;18(1):81-88.
46. Hall CS, **Charlebois ED**, Hahn JA, Moss AR, Bangsberg DR. Hepatitis C virus infection in San Francisco's HIV-infected urban poor. *J Gen Intern Med*. Apr 2004;19(4):357-365.
47. Koester KA, Maiorana A, Vernon K, **Charlebois E**, Gaffney S, Lane T, Morin SF. HIV surveillance in theory and practice: Assessing the acceptability of California's non-name HIV surveillance regulations. *Health Policy*. Oct 24 2005.
48. Morin SF, Steward WT, **Charlebois ED**, Remien RH, Pinkerton SD, Johnson MO, Rotheram-Borus MJ, Lightfoot M, Goldstein RB, Kittel L, Samimy-Muzaffar F, Weinhardt L, Kelly JA, Chesney MA. Predicting HIV transmission risk among HIV-infected men who have sex with men: findings from the healthy living project. *J Acquir Immune Defic Syndr*. Oct 1 2005;40(2):226-235.
49. Pan ES, Diep BA, **Charlebois ED**, Auerswald C, Carleton HA, Sensabaugh GF, Perdreau-Remington F. Population dynamics of nasal strains of methicillin-resistant *Staphylococcus aureus*--and their relation to community-associated disease activity. *J Infect Dis*. Sep 1 2005;192(5):811-818.
50. **Charlebois ED**, Maiorana A, McLaughlin M, Koester K, Gaffney S, Rutherford GW, Morin SF. Potential deterrent effect of name-based HIV infection surveillance. *J Acquir Immune Defic Syndr*. Jun 1 2005;39(2):219-227.
51. Johnson MO, Charlebois E, Morin SF, Catz SL, Goldstein RB, Remien RH, Rotheram-Borus MJ, Mickalian JD, Kittel L, Samimy-Muzaffar F, Lightfoot MA, Gore-Felton C, Chesney A. Perceived adverse effects of antiretroviral therapy. *J Pain Symptom Manage*. Feb 2005;29(2):193-205.
52. Frazee BW, Lynn J, **Charlebois ED**, Lambert L, Lowery D, Perdreau-Remington F. High prevalence of methicillin-resistant *Staphylococcus aureus* in emergency department skin and soft tissue infections. *Ann Emerg Med*. Mar 2005;45(3):311-320.
53. Srikantiah P, **Charlebois E**, Havlir DV. Rapid increase in tuberculosis incidence soon after infection with HIV--a new twist in the twin epidemics. *J Infect Dis*. Jan 15 2005;191(2):147-149.

54. Morin SF, Khumalo-Sakutukwa G, **Charlebois ED**, Routh J, Fritz K, Lane T, Vaki T, Fiamma A, Coates TJ. Removing barriers to knowing HIV status: same-day mobile HIV testing in Zimbabwe. *J Acquir Immune Defic Syndr*. Feb 1 2006;41(2):218-224.
55. Gasasira AF, Dorsey G, Kanya MR, Havlir D, Kiggundu M, Rosenthal PJ, **Charlebois ED**. False-positive results of enzyme immunoassays for human immunodeficiency virus in patients with uncomplicated malaria. *J Clin Microbiol*. Aug 2006;44(8):3021-3024.
56. Srikantiah P. LR, Walusimbi M., Okwera A., Luzze H., Whalen C.C., Boom H.W., Havlir D.V., **Charlebois ED**. Elevated HIV seroprevalence and risk behavior among Ugandan TB suspects: implications for HIV testing and prevention. *Int J Tuberc Lung Dis*. Feb 2007;11(2):168-174.
57. Luetkemeyer AF, **Charlebois ED**, Flores LL, et al. Comparison of an Interferon- $\gamma$  Release Assay to Tuberculin Skin Testing in HIV-Infected Individuals. *Am J Respir Crit Care Med*. Jan 11 2007.

#### NON-PEER REVIEWED PUBLICATIONS:

Morin, S.F., Coates T. & **Charlebois, E.** (1998). New Treatments, New Challenges, and New Questions about HIV Testing. Invited paper presented at the Kaiser Family Foundation Forum: Understanding the Impact of New Treatments on HIV Testing, Palo Alto, CA.

Coates, T., Morin, S.F. & **Charlebois, E.** (1998). New Technologies for Counseling and Testing: Should we redesign the system or should we just start over? Invited paper presented at the Kaiser Family Foundation Forum: Understanding the Impact of New Treatments on HIV Testing, Palo Alto, CA.

Morin, S.F., **Charlebois, E.D.**, Koester, K.A., Harcourt, J., Maiorana, A., McLaughlin, M., Gaffney, S., Schwarcz, S., Rutherford, G. (2005). Acceptability of California's HIV Reporting by Non-Name Code Regulations: Views from Four California Counties. AIDS Research Institute Monograph Series, University of California, San Francisco.

**Charlebois, E.D.**, Myers, J.J. Koester, K.A., Harcourt, J., Morfit, S., Gaffney, S., Bie, J., Morin, S.F., (2006). National Survey of Health Center HIV Testing, Prevention, Care, and Treatment Practices. AIDS Research Institute Monograph Series, University of California, San Francisco.

#### ABSTRACTS

2002 Genetically Identical *Staphylococcus aureus* Simultaneously Isolated from Nasal Culture and Soft-Tissue Infections. ED Charlebois, D Young, H Hobbart, B Haller, N Moss, DR Bangsberg, F Perdreau-Remington. 42<sup>nd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego 2002.

2002 Molecular Evidence for Clonal Distinction between Community and Nosocomial Methicillin-Resistant *Staphylococcus aureus* (MRSA) in 536 Clinical Infections. Charlebois ED, Perdreau-Remington F. Infectious Disease Society of America Meeting. Chicago. In: Clinical Infectious Diseases.

2002 Dramatic Increase in Methicillin-Resistant *Staphylococcus aureus* (MRSA) due to a predominant clone in County jails between 1996 and 2001. Pan ES, Moss N, Haller B, Charlebois ED, Perdreau-Remington F. 42<sup>nd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego 2002.

2002 Why aren't the HIV(+) urban poor receiving Opportunistic Infection prophylaxis? Charlebois ED, Perry S, Bangsberg DR, Clark R, Moss AR. XIV International AIDS Conference, Barcelona, Spain

2002 Increased Risk for *Staphylococcus aureus* Colonization Linked to CD4 Cell Count. Moss NJ, Perdreau-Remington F, Bangsberg DR, Charlebois ED. XIV International AIDS Conference, Barcelona, Spain

2002 Bangsberg DR, Charlebois ED, Grant R, Holodniy M, Perry S, Nugent Conroy K, Clark R, Guzman D, Zolopa A, Moss AR: Low Levels of Adherence Do Not Increase Risk of HIV Drug Resistance. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.

2003 Increase of staphylococcal chromosomal cassette mec (SCCmec) type IV seen over an 8-year period in a clinical setting. Carleton H, Charlebois ED, Perdreau-Remington F. 43<sup>rd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago.

2003 Homeless and runaway youth at increased risk for methicillin-resistant *Staphylococcus aureus* (MRSA) colonization. Pan ES, Charlebois ED, Perdreau-Remington F, Auerswald C, Carleton H, Perdreau-Remington F. Infectious Disease Society of America Meeting. San Diego.

2003 Liechty CA, Alexander C, Harrigan R, Guzman D, Charlebois ED, Moss AR, and Bangsberg DR. Are random antiretroviral drug levels associated with objectively measured adherence behavior? 10th Conference on Retroviruses and Opportunistic Infections, Boston, 2003 #529

2004 Responding to HIV transmission risk among HIV-infected men who have sex with men requires different strategies for primary and casual partners  
S F Morin, W T Steward, E D Charlebois, M O Johnson, R H Remien, J A Kelly, M J Rotheram-Borus. The XV International AIDS Conference, 2004 Abstract no. ThPeC7539.

2004 Understanding why people test for HIV in Sub-Saharan Africa: acceptance of mobile voluntary counseling and testing . S F Morin, E D Charlebois, G Khumalo-Sakutukwa, J Routh, K Fritz, T Vaki, A Fiamma, T J Coates. The XV International AIDS Conference, 2004. Abstract no. TuPeD5025.

2004 Potential deterrent effect of name-based HIV-infection surveillance . E D Charlebois, S D Morin, A Maiorana, M McLaughlin, S Gaffney, G W Rutherford. The XV International AIDS Conference, 2004. Abstract no. MoPeE4105.

2004 Poor adherence among HIV-infected adults in primary relationships. M O Johnson, E Charlebois, S F Morin, W T Steward, R H Remien, S Catz, M J Rotheram-Borus. The XV International AIDS Conference, 2004. Abstract no. WePeB5807.

2004 Coping modifies side effect-antiretroviral adherence relationship. M O Johnson, E Charlebois, S F Morin, S L Catz, R B Goldstein, R H Remien, M J Rotheram-Borus, J Mickalian, C Gore-Felton, M A Lightfoot, L Kittel, F Samimy-Muzaffar, M A Chesney. The XV International AIDS Conference, 2004. Abstract no. WePeB5808.

2004 Demographics of HIV-infected people, not risk profiles, determine who receives 'prevention with positives' counseling. W T Steward, S F Morin, E D Charlebois, M O Johnson, A A Ehrhardt, J A Kelly, M J Rotheram-Borus. The XV International AIDS Conference, 2004. Abstract no. C10582.

2004 Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale (VAS). T P Giordano, D Guzman, R Clark, E D Charlebois, D R Bangsberg. The XV International AIDS Conference, 2004. Abstract no. WeOrB1322.

2004 Removing barriers to learning one's HIV status: mobile voluntary HIV counseling and testing in Sub-Saharan Africa. G Khumalo-Sakutukwa, J Routh, E D Charlebois, K Fritz, T Vaki, T Mutevedzi, S F Morin. The XV International AIDS Conference, 2004 Abstract no. TuPeD5024.